Published in Nursing Home and Elder Business Week, November 28th, 2004
The trial was designed to evaluate Aridol as a test for asthma. The positive results mean the company will apply for marketing authorization later this year in Australia, and early in 2005 in Europe. Subject to regulatory approval, sales of Aridol are expected to commence in 2005. The annual revenue potential of Aridol as a management tool for Asthma is estimated to be in excess of $250 million. Patch holds 11.2 million shares in Pharmaxis and is the company's second...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Nursing Home and Elder Business Week